億勝生物公布2023年度業績,收入增長29.5%,利潤增長22.1%
Retrieved on:
星期一, 三月 18, 2024
The Group weathered the headwinds and managed to deliver sound performances amidst the challenging trading environment in 2023.
HONG KONG, Aug 16, 2023 - (ACN Newswire) - Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the interim results for the six months ended 30 June 2023 ("the period under review").
This single-arm, open-label, multicentre, phase I/II study aimed to evaluate the safety and preliminary efficacy of EB12-20145P (HLX04-O) via intravitreal injection (IVT) in patients with active wet age-related macular degeneration (wAMD).